Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial
- DOI
- 10.1186/s12885-018-4828-1
- Published
- 2018-10-11
- Container
- BMC Cancer
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1186/s12885-018-4828-1,
title = {Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial},
author = {Loïc Lebellec and François Bertucci and Emmanuelle Tresch-Bruneel and Isabelle Ray-Coquard and Axel Le Cesne and Emmanuelle Bompas and Jean-Yves Blay and Antoine Italiano and Olivier Mir and Thomas Ryckewaert and Yves Toiron and Luc Camoin and Anthony Goncalves and Nicolas Penel and Marie-Cécile Le Deley},
year = {2018},
journal = {BMC Cancer},
doi = {10.1186/s12885-018-4828-1},
url = {https://doi.org/10.1186/s12885-018-4828-1}
}RIS
TY - JOUR TI - Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial AU - Loïc Lebellec AU - François Bertucci AU - Emmanuelle Tresch-Bruneel AU - Isabelle Ray-Coquard AU - Axel Le Cesne AU - Emmanuelle Bompas AU - Jean-Yves Blay AU - Antoine Italiano AU - Olivier Mir AU - Thomas Ryckewaert AU - Yves Toiron AU - Luc Camoin AU - Anthony Goncalves AU - Nicolas Penel AU - Marie-Cécile Le Deley PY - 2018 JO - BMC Cancer DO - 10.1186/s12885-018-4828-1 UR - https://doi.org/10.1186/s12885-018-4828-1 ER -
APA
Lebellec, L., Bertucci, F., Tresch-Bruneel, E., Ray-Coquard, I., Cesne, A. L., Bompas, E., Blay, J., Italiano, A., Mir, O., Ryckewaert, T., Toiron, Y., Camoin, L., Goncalves, A., Penel, N., & Deley, M. L. (2018). Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial. BMC Cancer. https://doi.org/10.1186/s12885-018-4828-1
Source records
- crossref · retrieved 2026-11-10T15:06:54.110Z